Filing Analysis
SCYNEXIS, Inc. reported the results of its 2026 Annual Meeting of Stockholders, which included approval to significantly increase authorized shares and an amendment to the 2024 Equity Incentive Plan. Notably, the filing references a recent 1-for-8 reverse stock split that occurred on May 29, 2026.
🚩 Red Flags
- Recent 1-for-8 reverse stock split (May 29, 2026) indicates potential Nasdaq compliance issues or capital restructuring.
- Significant increase in authorized shares and equity incentive plan capacity often precedes dilutive financing.
- Large volume of shares available for resale via S-3 registration (up to 87M pre-split).
📋 Key Facts
- Annual Meeting held on June 25, 2026; all results reported are on a pre-reverse stock split basis.
- A 1-for-8 reverse stock split took effect on May 29, 2026.
- Stockholders approved increasing authorized shares from 18.75M to 60M (pre-split basis).
- Stockholders approved an amendment to the 2024 Equity Incentive Plan to increase authorized shares by 9.6M (pre-split basis).
- The company filed a Form S-3 registration statement for the resale of up to 87,000,000 shares (pre-split basis) by selling stockholders.
- Common Warrants held by selling stockholders have an exercise price of $1.20 per share (pre-split).
SCYNEXIS, Inc. has implemented a 1-for-8 reverse stock split effective May 29, 2026, and reduced its authorized common stock from 150 million to 18.75 million shares. The split-adjusted stock is scheduled to begin trading on the Nasdaq Capital Market on June 1, 2026.
🚩 Red Flags
- Reverse stock splits in micro-cap companies are frequently used to artificially inflate share prices to avoid Nasdaq minimum bid price delisting requirements.
- Significant reduction in authorized share capital (from 150M to 18.75M) suggests a drastic contraction of the equity structure.
📋 Key Facts
- Reverse stock split ratio is 1-for-8 (1:8).
- Authorized shares reduced from 150,000,000 to 18,750,000.
- Effective date of the amendment was May 29, 2026.
- Nasdaq trading on a split-adjusted basis begins June 1, 2026.
- New CUSIP number is 811292 309.
- Fractional shares are paid out in cash; no fractional shares issued.
- Par value remains unchanged at $0.001 per share.
SCYNEXIS, Inc. (SCYX) held a special stockholder meeting on May 19, 2026, at which shareholders approved a reverse stock split at a ratio between 1-for-5 and 1-for-10. The Board subsequently selected a 1-for-8 ratio, effective May 29, 2026, with split-adjusted trading on Nasdaq commencing June 1, 2026. Authorized shares will be reduced from 150,000,000 to 18,750,000.
🚩 Red Flags
- Reverse stock split at a 1-for-8 ratio is a strong indicator of share price distress, typically executed to regain or maintain Nasdaq minimum bid price compliance ($1.00 minimum)
- Authorized share count reduction from 150,000,000 to 18,750,000 severely limits future capital raising flexibility via equity issuances
- Multiple 8-K items filed simultaneously (Items 5.07 and 8.01), compounding the significance of the event
- Pre-split share count of ~79.4 million shares for a micro-cap biotech implies significant prior dilution from equity offerings or compensation
- Cash payments for fractional shares may indicate a large number of small retail shareholders, adding minor administrative/liquidity complexity
📋 Key Facts
- Special Meeting held May 19, 2026; 51,638,303 of 79,442,633 eligible shares (65.0%) were present in person or by proxy
- Proposal 1 approved with 44,826,378 votes FOR, 6,708,960 AGAINST, and 102,965 abstentions (~86.8% of votes cast were in favor)
- Board approved a 1-for-8 reverse stock split on May 19, 2026; effective date is May 29, 2026
- Split-adjusted trading on Nasdaq Capital Market under ticker 'SCYX' commences June 1, 2026
- Every 8 shares of common stock will be automatically converted into 1 share
- Authorized shares of common stock reduced from 150,000,000 to 18,750,000; par value remains $0.001 per share
- New CUSIP number post-split: 811292 309
- Reverse split affects all outstanding shares, equity compensation plans, stock options, RSUs, and warrants; exercise prices will be adjusted proportionally
- No fractional shares will be issued; cash will be paid in lieu of fractional shares
- Filing signed by David Angulo, M.D., Chief Executive Officer, on May 22, 2026
Dr. Steven C. Gilman notified SCYNEXIS of his intent to retire from the Board of Directors and will not stand for reelection at the 2026 annual meeting. He currently serves as the Chair of the Compensation Committee and will remain in his roles until the conclusion of the upcoming annual meeting.
📋 Key Facts
- Dr. Steven C. Gilman notified the company of his retirement on April 16, 2026.
- Dr. Gilman will not stand for reelection at the 2026 Annual Meeting of stockholders.
- He currently serves as Chair of the Compensation Committee and a member of the Nominating and Corporate Governance Committee.
- The company stated there were no disagreements regarding operations, policies, or practices.
SCYNEXIS, Inc. furnished a corporate presentation and held a conference call on March 31, 2026, to discuss a previously announced asset acquisition transaction and provide a corporate update.
📋 Key Facts
- Conference call held on March 31, 2026, regarding an asset acquisition transaction.
- Corporate presentation dated March 2026 was furnished as Exhibit 99.1.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- The report was signed by David Angulo, M.D., Chief Executive Officer.
SCYNEXIS entered into a $40 million private placement (PIPE) of common stock and warrants, with the potential for an additional $52.2 million in proceeds upon warrant exercise. The financing is expected to extend the company's cash runway into mid-2029 and includes participation from the CEO.
🚩 Red Flags
- Significant dilution: The offering involves up to 87 million shares/warrants, which is substantial for a micro-cap company.
- Authorized share constraint: The company requires stockholder approval to increase authorized shares, indicating they are likely near their current legal limit.
📋 Key Facts
- Agreed to issue 34,750,000 shares of common stock and 8,750,000 pre-funded warrants.
- Issued 43,500,000 common warrants with an exercise price of $1.20 per share.
- Combined purchase price was $0.92 per share/unit, representing approximately $40 million in initial gross proceeds.
- CEO Dr. David Angulo participated in the offering, purchasing 108,695 units.
- The company must convene a stockholder meeting within 90 days to approve an increase in authorized shares to accommodate the warrant exercises.
- Estimated cash runway extended into mid-2029 based on current plans and offering proceeds.
SCYNEXIS acquired Poxel SA's AMP kinase activator R&D program, including the lead compound PXL-770, for an upfront payment of $8 million and potential milestones totaling $188 million. The deal grants SCYNEXIS an exclusive, worldwide license to develop and commercialize the acquired assets.
🚩 Red Flags
- Significant contingent liabilities with up to $188 million in milestone obligations.
- Forward-looking statements explicitly mention the need to raise additional capital to fund the development and commercialization of these new assets.
📋 Key Facts
- One-time upfront payment of $8,000,000 due within 30 days of the March 30, 2026 agreement.
- Total potential milestone payments of $188,000,000, including $2,000,000 for Phase 2 initiation and $6,000,000 for Phase 3 initiation or U.S. approval.
- Commercial milestones include a $25,000,000 payment upon the first U.S. commercial sale.
- Sales-based milestones reach up to $75,000,000 for annual net sales exceeding $1.5 billion.
- Acquisition includes all patents, know-how, regulatory filings, and inventory related to the PXL-770 compound.
SCYNEXIS has entered into a binding Memorandum of Understanding (MOU) with GSK to amend their existing exclusive license agreement. The amendment resolves a previous disagreement regarding the Phase 3 MARIO study, resulting in the termination of that specific study and an immediate $22 million payment to SCYNEXIS.
🚩 Red Flags
- Termination of a Phase 3 clinical study (MARIO Study) typically indicates a failure to meet primary endpoints or significant strategic pivot.
- Loss of future milestone revenue specifically associated with the MARIO Study indication.
📋 Key Facts
- SCYNEXIS and GSK entered into a 'Binding 2025 MOU' on October 14, 2025.
- The agreement resolves a disagreement regarding the Phase 3 MARIO study for invasive candidiasis.
- SCYNEXIS will wind down and terminate the MARIO Study.
- GSK will pay SCYNEXIS $22 million to resolve the dispute.
- An additional $2.3 million payment will be made for wind-down activities.
- SCYNEXIS will not receive further milestone payments specifically related to the MARIO Study.
- The transfer of the BREXAFEMME NDA to GSK is expected by the end of 2025.
- GSK plans regulatory interactions with the FDA in 2026 regarding the relaunch of BREXAFEMME for VVC and rVVC indications.
SCYNEXIS, Inc. held its 2025 Annual Meeting of Stockholders on June 25, 2025. The meeting resulted in the successful election of all seven proposed directors and the ratification of Deloitte & Touche LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 25, 2025.
- All seven proposed directors were re-elected to serve until the 2026 Annual Meeting or successors are qualified.
- Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025 (25,543,125 votes 'For').
- Advisory approval of executive compensation was granted (12,417,323 votes 'For').
SCYNEXIS, Inc. received a notification from Nasdaq stating that its common stock has been below the $1.00 minimum bid price for 30 consecutive business days. The company has until December 17, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice/non-compliance with minimum bid price requirement
- Potential necessity of a reverse stock split to regain compliance
- Risk of being downgraded from the Nasdaq Global Market to the Nasdaq Capital Market
📋 Key Facts
- Nasdaq notified SCYNEXIS on June 20, 2025, of a deficiency in the minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)).
- The stock closed below $1.00 for at least 30 consecutive business days.
- Compliance deadline is December 17, 2025 (180 calendar days from the notice date).
- Compliance can be achieved if the closing bid price is at least $1.00 for 10 consecutive business days.
- Failure to comply may result in a transfer to the Nasdaq Capital Market or delisting.
SCYNEXIS entered into a new $50 million 'at-the-market' (ATM) equity offering agreement with Cantor Fitzgerald & Co. while simultaneously terminating two prior ATM agreements with Cantor and Ladenburg Thalmann.
🚩 Red Flags
- The use of an ATM offering often indicates a need for immediate liquidity to fund operations, common in micro-cap biotech firms.
📋 Key Facts
- Entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. on November 6, 2024.
- The new agreement allows for the sale of up to $50 million in aggregate common stock via an 'at-the-market' (ATM) offering.
- Agent compensation is set at 3% of gross sales price.
- Terminated a prior May 17, 2021, Sales Agreement with Cantor and a similar agreement with Ladenburg Thalmann & Co. Inc.
- Approximately $3.8 million in shares were sold under the terminated prior agreements.
SCYNEXIS, Inc. has updated its corporate investor presentation as of September 10, 2024. This filing is a routine disclosure under Item 7.01 to provide updated information to the public via their website.
📋 Key Facts
- The company updated its 'Corporate Presentation' on September 10, 2024.
- The presentation is furnished as Exhibit 99.1 and is not considered 'filed' for purposes of Section 18 liability.
- The update was made pursuant to Item 7.01 (Regulation FD Disclosure).
SCYNEXIS, Inc. held its 2024 Annual Meeting of Stockholders on June 19, 2024. The meeting resulted in the successful election of all seven proposed directors and the ratification of several key shareholder proposals.
📋 Key Facts
- Annual Meeting held on June 19, 2024.
- All seven proposed directors were re-elected to serve until the 2025 Annual Meeting or successors are elected.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2024 (25,192,381 votes 'For').
- Advisory approval of executive compensation was granted (13,476,050 votes 'For').
- The SCYNEXIS, Inc. 2024 Equity Incentive Plan was approved (12,891,296 votes 'For').
SCYNEXIS, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the company's annual performance via a press release.
📋 Key Facts
- Report date: March 28, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes Exhibit 99.1, which is the official press release regarding financial results.
- Company is listed on Nasdaq Global Market under ticker SCYX.
SCYNEXIS, Inc. updated its corporate investor presentation on January 5, 2024. This filing is a routine disclosure of marketing/investor relations materials under Item 7.01.
📋 Key Facts
- The company updated its 'Corporate Presentation' on January 5, 2024.
- The presentation was furnished as Exhibit 99.1 and is intended to provide information to investors via the company website.
SCYNEXIS entered into a binding Memorandum of Understanding (MOU) with GSK to amend its existing exclusive license agreement for ibrexafungerp. The amendment is necessitated by delays in commercialization and clinical development caused by a potential cross-contamination risk involving beta-lactam compounds.
🚩 Red Flags
- Significant reduction in potential milestone payments across all categories (regulatory, commercial, and sales) due to delays/renegotiation.
- Ongoing risk regarding beta-lactam cross-contamination which led to a product recall and clinical holds.
- The company remains responsible for the costs of ongoing clinical studies despite the setbacks.
📋 Key Facts
- Entered into a Binding MOU with GlaxoSmithKline Intellectual Property (No. 3) Limited on December 26, 2023.
- The amendment addresses delays in the commercialization of BREXAFEMME and clinical development due to potential beta-lactam contamination risks.
- SCYNEXIS has already received $90 million upfront and a $25 million development milestone payment from GSK.
- Revised regulatory approval milestones: up to $49 million (previously $70 million).
- Revised commercial milestone payments for invasive candidiasis: up to $57.5 million (previously $115 million).
- Revised sales milestone payments: tiered up to $179.5M / $169.75M / $145.5M depending on GSK's relaunch date.
- SCYNEXIS remains responsible for the costs of ongoing clinical studies.